In a recent development, pharmaceutical giant Novartis has initiated legal proceedings against the U.S. Food and Drug Administration (FDA), alleging that the federal body unlawfully approved a generic version of its heart failure medication, Entresto. The lawsuit has been filed in the D.C. federal court. The heart drug, a cornerstone in Novartis’ cardiovascular portfolio, has been pivotal in treating heart failure, and the drugmaker contends that the FDA’s approval of a generic counterpart was inappropriate.
For further details on the ongoing lawsuit and the implications for both Novartis and the FDA, visit the full article on Law360.